Sulfamerazine Synthesis Essay - Essay for you

Essay for you

Sulfamerazine Synthesis Essay

Rating: 5.0/5.0 (11 Votes)

Category: Essay

Description

Syntheses and characterisation of mercury complexes of sulfadiazine, sulfamerazine and sulfamethazine

Syntheses and characterisation of mercury complexes of sulfadiazine, sulfamerazine and sulfamethazine Abstract

The triple sulfa drugs, sulfadiazine, sulfamerazine and sulfamethazine, form a large number of metal complexes in different solvent media. The present studies show the synthesis and characterization of the Hg(II) complexes of sulfadiazine 1. sulfamerazine 2 and sulfamethazine 3 in dimethylformamide solution in presence of ammonia. The compounds were characterised by spectroscopic methods and crystal structures of the complexes were determined. All the compounds, 1. 2 and 3. crystallise in monoclinic crystal systems with the space groups of C 2/c. C 2/c and P 21 /c. respectively. Compounds 1 and 3 have eight coordinate ‘2+6’ geometries, with two tridentate sulfonamide ions and two DMF molecules in the coordination sphere. Complex 2 has a six co-ordinate, ‘2+4’ geometry which contains a short linear N–Hg–N moiety from co-ordinated sulfonamides. The IR spectral data suggest the binding of mercury atom to the sulfonamidic nitrogen atoms in agreement with the crystal structure determination.

Graphical abstract

Hg(II) complexes of sulfadiazine 1. sulfamerazine 2 and sulfamethazine 3 were synthesised and their nature investigated by spectroscopic methods, including single crystal X-ray diffraction. In the solid state compounds 1 and 3 have eight coordinate ‘2+6’ geometries, with two tridentate sulfonamide ions and two DMF molecules in the coordination sphere, while complex 2 has a six co-ordinate, ‘2+4’ geometry.

Keywords
  • Triple sulfa drug ;
  • Mercury ;
  • Sulfadiazine ;
  • Sulfamerazine ;
  • Sulfamethazine

Other articles

Sulfamerazine synthesis essay

Sulfamerazine/sulfamethazine/sulfadiazine Uses and prices

sulfamerazine/sulfamethazine/sulfadiazine - sulfamerazine/sulfamethazine/sulfadiazine is a sulfonamide antibiotic. The sulfonamides are synthetic bacteriostatic antibiotics with a wide spectrum against most gram-positive and many gram-negative organisms. However, many strains of an individual species may be resistant. Sulfonamides inhibit multiplication of bacteria by acting as competitive inhibitors of p -aminobenzoic acid in the folic acid metabolism cycle. Bacterial sensitivity is the same for the various sulfonamides, and resistance to one sulfonamide indicates resistance to all. Most sulfonamides are readily absorbed orally. However, parenteral administration is difficult, since the soluble sulfonamide salts are highly alkaline and irritating to the tissues. The sulfonamides are widely distributed throughout all tissues. High levels are achieved in pleural, peritoneal, synovial, and ocular fluids. Although these drugs are no longer used to treat meningitis, CSF levels are high in meningeal infections. Their antibacterial action is inhibited by pus.

Indication: For the treatment of rheumatic fever and meningococcal meningitis

Active ingredients: sulfamerazine/sulfamethazine/sulfadiazine

List of sulfamerazine/sulfamethazine/sulfadiazine brand name and generic drugs

Suspension; Oral; Sulfadiazine 167 mg; Sulfamerazine 167 mg; Sulfamethazine 167 mg / 5 ml

Suspension; Oral; Sulfadiazine 167 mg; Sulfamerazine 167 mg; Sulfamethazine 167 mg / 5 ml

Tablet; Oral; Sulfadiazine 167 mg; Sulfamerazine 167 mg; Sulfamethazine 167 mg

Tablet; Oral; Sulfadiazine 167 mg; Sulfamerazine 167 mg; Sulfamethazine 167 mg

Suspension; Oral; Sulfadiazine 167 mg; Sulfamerazine 167 mg; Sulfamethazine 167 mg / 5 ml

Tablet; Oral; Sulfadiazine 167 mg; Sulfamerazine 167 mg; Sulfamethazine 167 mg

Suspension; Oral; Sulfadiazine 167 mg; Sulfamerazine 167 mg; Sulfamethazine 167 mg / 5 ml

Tablet; Oral; Sulfadiazine 167 mg; Sulfamerazine 167 mg; Sulfamethazine 167 mg

Suspension; Oral; Sulfadiazine 167 mg; Sulfamerazine 167 mg; Sulfamethazine 167 mg / 5 ml

Tablet; Oral; Sulfadiazine 167 mg; Sulfamerazine 167 mg; Sulfamethazine 167 mg

sulfamerazine - Sulfonamides act as competitive inhibitors of the enzyme dihydropteroate synthetase (DHPS), an enzyme involved in folate synthesis in bacteria.

Oral Infections due to Haemolytic Streptococci, Meningococci, Pneumococci, Gonococci, E. Coli

Adult: As sulfadiazine 167 mg, sulfadimidine 167 mg, sulfamerazine 167 mg combination per tablet: Initially 4-8 tablets, then 2 tablets every 6 hr. Renal impairment: Dose reduction may be needed. Hepatic impairment: Dose reduction may be needed.

Oral Susceptible infections

Adult: As sulfadiazine 167 mg, sulfadimidine 167 mg, sulfamerazine 167 mg combination per tablet: Initially 4-8 tablets, then 2 tablets every 6 hr. Renal impairment: Dose reduction may be needed. Hepatic impairment: Dose reduction may be needed.

Indications: Susceptible infections.

sulfamethazine - sulfamethazine is a sulfonamide drug that inhibits bacterial synthesis of dihydrofolic acid by competing with para-aminobenzoic acid (PABA) for binding to dihydropteroate synthetase (dihydrofolate synthetase). sulfamethazine is bacteriostatic in nature. Inhibition of dihydrofolic acid synthesis decreases the synthesis of bacterial nucleotides and DNA.

sulfadiazine - Pharmacology: Exerts bacteriostatic action by competing with PABA, an essential component in folic acid synthesis, therefore preventing synthesis of folic acid needed by bacteria for growth.

Indication: Treatment of chancroid, trachoma, inclusion conjunctivitis, nocardiosis, UTI, toxoplasmosis encephalitis, malaria, meningococcal meningitis, acute otitis media; prophylaxis against meningococcal meningitis and recurrences of rheumatic fevers; with streptomycin as adjunctive therapy for Haemophilus influenza meningitis.

Take all of the sulfadiazine that has been prescribed for you even if you begin to feel better. Your symptoms may start to improve before the infection is completely treated.

Used for: Treating and preventing certain bacterial infections.

sulfadiazine is a sulfonamide antibiotic. It works by inhibiting the growth and replication of bacteria.

sulfadiazine is a sulfonamide antibiotic. The sulfonamides are synthetic bacteriostatic antibiotics with a wide spectrum against most gram-positive and many gram-negative organisms. However, many strains of an individual species may be resistant. Sulfonamides inhibit multiplication of bacteria by acting as competitive inhibitors of p -aminobenzoic acid in the folic acid metabolism cycle. Bacterial sensitivity is the same for the various sulfonamides, and resistance to one sulfonamide indicates resistance to all. Most sulfonamides are readily absorbed orally. However, parenteral administration is difficult, since the soluble sulfonamide salts are highly alkaline and irritating to the tissues. The sulfonamides are widely distributed throughout all tissues. High levels are achieved in pleural, peritoneal, synovial, and ocular fluids. Although these drugs are no longer used to treat meningitis, CSF levels are high in meningeal infections. Their antibacterial action is inhibited by pus.

Oral Infections caused by susceptible pathogens

Adult: Initially, 2-4 g/day. May increase up to 6 g/day, given in divided doses.

Child: Start with 75 mg/kg, subsequently, 150 mg/kg in divided doses. Max: 6 g/day. Renal impairment: Dosage reduction may be necessary.

Oral Prophylaxis of rheumatic fever in children

Child: <30 kg: 0.5 g every 24 hr; >30 kg: 1 g/day. Renal impairment: Dosage reduction may be necessary.

Oral Nocardiosis

Adult: 4-8 g daily for at least 6 wk. May continue for many mth to prevent relapse of infection. Renal impairment: Dosage reduction may be necessary.

Oral Prophylaxis of meningococcal infections

Adult: 1 g bid for 2 days.

Child: 2-12 mth: 500 mg once daily for 2 days; 1-12 yr: 500 mg bid for 2 days. Renal impairment: Dosage reduction may be necessary.

Oral Toxoplasmosis

Adult: Including immunocompromised patients: 4-6 g/day in 4 divided doses for at least 6 wk. Subsequently, 2-4 g/day, to be continued indefinitely.

Child: For congenital toxoplasmosis: <2 mth: 50 mg/kg bid for 12 mth. Renal impairment: Dosage reduction may be necessary.

Oral Prevention of toxoplasmosis in patients with HIV infection

Adult: 0.5-1 g every 6 hr, to be taken with oral pyrimethamine (25-50 mg daily) and oral leucovorin (10-25 mg/day).

Child: 85-120 mg/kg/day, given in 2-4 divided doses with oral pyrimethamine (1 mg/kg/day; max: 25 mg/day) and oral leucovorin (5 mg once every 3 days). Renal impairment: Dosage reduction may be necessary.

Oral Susceptible infections

Adult: Initially, 2-4 g/day. May increase up to 6 g/day, given in divided doses.

Child: Start with 75 mg/kg, subsequently, 150 mg/kg in divided doses. Max: 6 g/day. Renal impairment: Dosage reduction may be necessary.

Oral Prophylaxis of rheumatic fever

Adult: >30 kg: 1 g once daily; <30 kg: 500 mg once daily.

Child: <30 kg: 0.5 g every 24 hr; >30 kg: 1 g/day. Renal impairment: Dosage reduction may be necessary.

Oral Nocardiosis

Adult: 4-8 g daily for at least 6 wk. May continue for many mth to prevent relapse of infection. Renal impairment: Dosage reduction may be necessary.

Oral Toxoplasmosis

Adult: Including immunocompromised patients: 4-6 g/day in 4 divided doses for at least 6 wk. Subsequently, 2-4 g/day, to be continued indefinitely.

Child: For congenital toxoplasmosis: <2 mth: 50 mg/kg bid for 12 mth. Renal impairment: Dosage reduction may be necessary.

Oral Prophylaxis of toxoplasmosis in patients with HIV infection

Adult: 0.5-1 g every 6 hr, to be taken with oral pyrimethamine (25-50 mg daily) and oral leucovorin (10-25 mg/day).

Child: 85-120 mg/kg/day, given in 2-4 divided doses with oral pyrimethamine (1 mg/kg/day; max: 25 mg/day) and oral leucovorin (5 mg once every 3 days). Renal impairment: Dosage reduction may be necessary.

Adult: PO Susceptible infections Initial: 2-4 g/day, up to 6 g/day in divided doses. Prophylaxis of rheumatic fever >30 kg: 1 g once daily; <30 kg: 500 mg once daily. Nocardiosis 4-8 g/day for ≥6 wk. Prophylaxis of meningococcal infections 1 g twice daily for 2 days. Toxoplasmosis 4-6 g/day in 4 divided doses for ≥6 wk, then continue w/ 2-4 g/day indefinitely. Prevention of toxoplasmosis in patients w/ HIV infection 0.5-1 g 6 hrly w/ oral pyrimethamine and oral leucovorin.

Sulfamerazine synthesis essay

PharmGKB contains no dosing guidelines for this. To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this. If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

= Mouse-over for quick help

Analysis of Amorphous and Crystalline Sulfamerazine - 2012 Development of Novel Chiral Tethers for Controlling Intermolecular

Analysis of Amorphous and Crystalline Sulfamerazine P. MacFhionnghaile1. Y. Hu 1. A. Erxleben 1. and P. McArdle 1


1. School of Chemistry, NUI Galway.


The detection and quantification of amorphous and crystalline content in pharmaceutical solids is an area of increasing interest in recent years due to the different properties of the amorphous and crystalline phases. Amorphous and crystalline states can differ for example in stability, solubility and bioavailability. Because of this it is necessary to have accurate means to quantify the different solid state forms, and to understand their formation and properties [1] .

In this study the amorphous phase of sulfamerazine was produced, for the first time via cryo-milling (Figure 1). The effects of cryo-milling on the two polymorphs of sulfamerazine, form I and form II, were investigated and the stability of the amorphous phase obtained from both forms was studied. X-ray powder diffraction (XRPD), near-infrared (NIR) and infrared (IR) spectroscopy combined with multivariate analysis were used to quantify amorphous and crystalline sulfamerazine in binary mixtures (amorphous / form I and amorphous / form II). The best calibration model was obtained for the low content analysis of form II in form I with data pre-processed using the 2 nd derivative of the spectra and standard normal variate (SNV) transformation, giving root mean square error of calibration (RMSEC), root mean square error of validation (RMSEV) and root mean square error of prediction (RMSEP) values of 0.24%, 0.28%, and 0.24%.


Figure 1: XRPD of cryo-milled sulfamerazine taken at different intervals

References
1. G.D.P. Buckton, Int. J. Pharm., 1999, 179, 141-158

Financial support from Science Foundation Ireland (funding of the Solid State Pharmaceuticals Cluster) is gratefully acknowledged.


Ferromagnetic exchange in twisted, oxime-bridged [Mn(III)2 ] and [Mn(III)2 Zn(II)2 ] dimers

Edel Houton a. Euan K. Brechin b. Alan G. Ryder a and Leigh F. Jones a .


a School of Chemistry, University Road, National University of Ireland, Galway, Ireland.

b EaStCHEM School of Chemistry, The University of Edinburgh, The Kings Buildings, West Mains Road, Edinburgh, EH9 3JJ, UK.


Single-molecule magnets (SMMs) are a family of molecular species that can retain magnetization below a blocking temperature, in the absence of a magnetic field. Too date, a large number of molecules exhibiting the phenomenon of single-molecule magnetism have been synthesized. These mono-disperse magnetic materials consist of a collection of paramagnetic transition metal ions bound by a range of organic ligands. This class of compound represent the smallest possible magnetic storage devices, through storage of information in a single molecule rather than in an array of particles.

Developing upon previous work by Jones / Brechin and co-workers, 1 we report here the developement of a family of Manganese based SMMs. Two complexes are described which act as simple model complexes, with which to examine the magneto-structural relationship in polymetallic, oxime-bridged Mn III complexes. Dc magnetic susceptibility studies reveal that ferromagnetic exchange is mediated through their heavily twisted Mn-O-N-Mn moieties (Fig. 1). 2

1. R. Inglis, C. J. Milios, L. F. Jones, S. Piligkos and E. K. Brechin, Chem. Commun., 2012, 48 . 181-190.

2. R. Inglis, E. Houton, J. Liu, A. Prescimone, J. Cano, S. Piligkos, S. Hill, L. F. Jones and E. K. Brechin, Dalton Trans., 2011, 40 . 9999-10006.

DrugBank: Sulfamerazine

Targets

Kind Protein Organism Escherichia coli (strain K12) Pharmacological action yes Actions inhibitor General Function: Metal ion binding Specific Function: Catalyzes the condensation of para-aminobenzoate (pABA) with 6-hydroxymethyl-7,8-dihydropterin diphosphate (DHPt-PP) to form 7,8-dihydropteroate (H2Pte), the immediate precursor of folate derivatives. Gene Name: folP Uniprot ID: P0AC13 Molecular Weight: 30614.855 Da

References
  1. Hong YL, Hossler PA, Calhoun DH, Meshnick SR: Inhibition of recombinant Pneumocystis carinii dihydropteroate synthetase by sulfa drugs. Antimicrob Agents Chemother. 1995 Aug;39(8):1756-63. [PubMed:7486915 ]
  2. Friaza V, Morilla R, Respaldiza N, de la Horra C, Calderon EJ: Pneumocystis jiroveci dihydropteroate synthase gene mutations among colonized individuals and Pneumocystis pneumonia patients from Spain. Postgrad Med. 2010 Nov;122(6):24-8. doi: 10.3810/pgm.2010.11.2219. [PubMed:21084778 ]
  3. Thijssen HH: A simplified radioassay method of dihydropteroate synthetase activity in Escherichia coli and its application for an inhibition study of p-aminobenzoi acid derivatives. Anal Biochem. 1973 Jun;53(2):579-85. [PubMed:4577373 ]
Carriers

Kind Protein Organism Human Pharmacological action unknown General Function: Toxic substance binding Specific Function: Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc. Gene Name: ALB Uniprot ID: P02768 Molecular Weight: 69365.94 Da

References
  1. Bratlid D, Bergan T: Displacement of albumin-bound antimicrobial agents by bilirubin. Pharmacology. 1976;14(5):464-72. [PubMed:1031216 ]
  2. Angelakou A, Valsami G, Koupparis M, Macheras P: Use of 1-anilino-8-napthalenesulphonate as an ion probe for the potentiometric study of the binding of sulphonamides to bovine serum albumin and plasma. J Pharm Pharmacol. 1993 May;45(5):434-8. [PubMed:8099962 ]

This project is supported by the Canadian Institutes of Health Research (award #111062), Alberta Innovates - Health Solutions. and by The Metabolomics Innovation Centre (TMIC). a nationally-funded research and core facility that supports a wide range of cutting-edge metabolomic studies. TMIC is funded by Genome Alberta. Genome British Columbia. and Genome Canada. a not-for-profit organization that is leading Canada's national genomics strategy with $900 million in funding from the federal government. Maintenance, support, and commercial licensing is provided by OMx Personal Health Analytics, Inc.

Sulfamerazine synthesis essay

CAS Name: 4-Amino-N- (4-methyl-2-pyrimidinyl)benzenesulfonamide

Additional Names:N 1 -(4-methyl-2-pyrimidyl)sulfanilamide; N1- (4-methyl-2-pyrimidinyl)sulfanilamide; 2-sulfanilamido-4-methylpyrimidine; sulfamethyldiazine

Manufacturers' Codes: RP-2632

Trademarks: Mesulfa (Triosol); Percoccide (A.C.F.)

Molecular Formula: C 11 H 12 N 4 O 2 S

Molecular Weight: 264.30

Percent Composition: C 49.99%, H 4.58%, N 21.20%, O 12.11%, S 12.13%

Literature References: Prepd by condensing 2-amino-4-methylpyrimidine with acetylsulfanilyl chloride followed by hydrolysis of the acetyl group: Roblin et al.,J. Am. Chem. Soc.62, 2002 (1940); Sprague et al.,ibid.63, 3028 (1941); Sprague, US2407966 (1946 to Sharp & Dohme). For prepn of 2-amino-4-methylpyrimidine see Benary, Ber.63, 2601 (1930); Backer, Grevenstuk, Rec. Trav. Chim.61, 291 (1942); cf. E. H. Northey, Sulfonamides (Reinhold, New York, 1948). Antimicrobial activity: Gill et al.,Indian J. Vet. Sci.32, 240 (1962); Vaichulis, Vedros, Chemotherapia11, 315 (1966). Toxicity studies: Simunek et al.,Vet. Med. (Prague)13, 619 (1968). Kinetics of sulfamerazine decompn: Zajac, Diss. Pharm. Pharmacol.22, 455 (1970). Comprehensive description: R. D. G. Woolfenden, Anal. Profiles Drug Subs.6, 515-577 (1977).

Properties: Crystals, mp 234-238°. uv max (water): 243, 257 nm (E 1%1cm 875, 822); (0.1M HCl): 243, 307 nm (E 1%1cm 625, 200); (ethanol): 271 nm (E 1%1cm 835). Slowly darkens on exposure to light. Soly in water at 37°: 35 mg/100 ml at pH 5.5; 170 mg/100 ml at pH 7.5. Readily sol in dil mineral acids and in solns of potassium, ammonium and sodium hydroxides. Sparingly sol in acetone, slightly sol in alcohol, very slightly sol in ether, chloroform.

Melting point: mp 234-238°

Absorption maximum: uv max (water): 243, 257 nm (E 1%1cm 875, 822); (0.1M HCl): 243, 307 nm (E 1%1cm 625, 200); (ethanol): 271 nm (E 1%1cm 835)

Derivative Type: Monosodium salt

CAS Registry Number: 127-58-2

Sulfamerazine sodium salt

Sulfamerazine sodium salt Biological Activity of Sulfamerazine sodium salt

Sulfamerazine Sodium is a sulfonamide antibacterial.
Target. Antibacterial
Sulfamerazine, the monomethyl derivative of sulfadiazine, is 2-sulfanilamido-4-methylpyrimidine. Sulfamerazine is a sulfonamide drug that inhibits bacterial synthesis of dihydrofolic acid by competing with para-aminobenzoic acid (PABA) for binding to dihydropteroate synthetase (dihydrofolate synthetase). Sulfamerazine is bacteriostatic in nature. Inhibition of dihydrofolic acid synthesis decreases the synthesis of bacterial nucleotides and DNA [1].

Chemical Information

5-hydroxypyrazine-2-carboxylic acid. a metabolite of anti-tuberculosis drug pyrazinamide (PZA).

7-Aminocephalosporanic acid is the core chemical structure for the synthesis of cephalosporin antibiotics, is a potent (beta)-lactamase inhibitor.

Acetohydroxamic acid is a potent and irreversible inhibitor of bacterial and plant urease and also used as adjunctive therapy in chronic urinary infection.

Dactinomycin D(Actinomycin D; Oncostatin K) is the most significant member of actinomycines, which are a class of polypeptide antibiotics isolated from soil bacteria of the genus Streptomyces.

AFN-1252(Debio 1452) is a potent inhibitor of enoyl-acyl carrier protein reductase (FabI), inhibited all clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis at concentrations of ≤0.12 (mu)g/ml.

Amikacin sulfate(BAY416651 sulfate) is a semi-synthetic aminoglycoside antibiotic derived from kanamycin A.

Anisomycin is a pyrrolidine antibiotic, acts as an anti-fungal antibiotic which inhibits Protein Synthesis, also is a potent activator of SAPKs/JNKs.

Antibiotic-202 is an antibiotic compound, for treating bacterial infections.

AVX 13616 shows the potent in vivo antibacterial activity of Avexa’s lead antibacterial candidate; particularly against drug-resistant Staphylococcus pathogens.

Azithromycin, derived from erythromycin, is a antibiotic. Azithromycin binds to the 50S subunit of the bacterial ribosome, and thus inhibits translation of mRNA.

Sulfamerazine synthesis essay

CAS Name: 4-Amino-N- (4-methyl-2-pyrimidinyl)benzenesulfonamide

Additional Names:N 1 -(4-methyl-2-pyrimidyl)sulfanilamide; N1- (4-methyl-2-pyrimidinyl)sulfanilamide; 2-sulfanilamido-4-methylpyrimidine; sulfamethyldiazine

Manufacturers' Codes: RP-2632

Trademarks: Mesulfa (Triosol); Percoccide (A.C.F.)

Molecular Formula: C 11 H 12 N 4 O 2 S

Molecular Weight: 264.30

Percent Composition: C 49.99%, H 4.58%, N 21.20%, O 12.11%, S 12.13%

Literature References: Prepd by condensing 2-amino-4-methylpyrimidine with acetylsulfanilyl chloride followed by hydrolysis of the acetyl group: Roblin et al.,J. Am. Chem. Soc.62, 2002 (1940); Sprague et al.,ibid.63, 3028 (1941); Sprague, US2407966 (1946 to Sharp & Dohme). For prepn of 2-amino-4-methylpyrimidine see Benary, Ber.63, 2601 (1930); Backer, Grevenstuk, Rec. Trav. Chim.61, 291 (1942); cf. E. H. Northey, Sulfonamides (Reinhold, New York, 1948). Antimicrobial activity: Gill et al.,Indian J. Vet. Sci.32, 240 (1962); Vaichulis, Vedros, Chemotherapia11, 315 (1966). Toxicity studies: Simunek et al.,Vet. Med. (Prague)13, 619 (1968). Kinetics of sulfamerazine decompn: Zajac, Diss. Pharm. Pharmacol.22, 455 (1970). Comprehensive description: R. D. G. Woolfenden, Anal. Profiles Drug Subs.6, 515-577 (1977).

Properties: Crystals, mp 234-238°. uv max (water): 243, 257 nm (E 1%1cm 875, 822); (0.1M HCl): 243, 307 nm (E 1%1cm 625, 200); (ethanol): 271 nm (E 1%1cm 835). Slowly darkens on exposure to light. Soly in water at 37°: 35 mg/100 ml at pH 5.5; 170 mg/100 ml at pH 7.5. Readily sol in dil mineral acids and in solns of potassium, ammonium and sodium hydroxides. Sparingly sol in acetone, slightly sol in alcohol, very slightly sol in ether, chloroform.

Melting point: mp 234-238°

Absorption maximum: uv max (water): 243, 257 nm (E 1%1cm 875, 822); (0.1M HCl): 243, 307 nm (E 1%1cm 625, 200); (ethanol): 271 nm (E 1%1cm 835)

Derivative Type: Monosodium salt

CAS Registry Number: 127-58-2